Comparative Pharmacology
Head-to-head clinical analysis: BRANCHAMIN 4 versus ELCYS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRANCHAMIN 4 versus ELCYS.
BRANCHAMIN 4% vs ELCYS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential branched-chain amino acids (leucine, isoleucine, valine) to correct deficiencies and support protein synthesis in catabolic states; serves as a substrate for energy production and muscle metabolism.
ELCYS (eltrombopag olamine) is a small molecule agonist of the thrombopoietin receptor (TPO-R) on hematopoietic stem cells and megakaryocytes, activating JAK-STAT signaling to stimulate megakaryopoiesis and platelet production.
1-1.5 g/kg/day intravenously, infused at a rate not exceeding 10 g/hour.
100 mg orally three times daily
None Documented
None Documented
Terminal elimination half-life of individual amino acids ranges from 0.5 to 2 hours; clinical context: rapid clearance requires continuous infusion to maintain plasma levels
Terminal elimination half-life is approximately 12-15 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in severe cases).
Primarily renal; >90% of infused amino acids are excreted in urine as metabolites (urea, ammonia) within 24 hours; minimal biliary/fecal elimination (<5%)
Primarily renal (approx. 35-50% unchanged drug) and biliary/fecal (about 50-60% as metabolites).
Category C
Category C
Amino Acid Supplement
Amino Acid Supplement